The Oxford Vaccine Group, part of University of Oxford, gave 99 volunteers a drink laced with live Salmonella Typhi bacteria a month after vaccinating them. Between 40% and 50% of the volunteers for the trial were students, Healthcare professionals were allowed to take part if they were not in patient-facing jobs or if they were willing to take around 3-4 weeks off work to be infected

A third had been vaccinated with Typbar-TCV, a new conjugate typhoid vaccine, a third with established vaccine Typhim Vi and the rest with meningitis vaccine Menveo, which does not protect against typhoid. Neither the volunteers nor the doctors carrying out the injections knew who was getting which vaccine.

The volunteers were monitored by staff during daily visits to its centre at Oxford’s Churchill Hospital, and had 24-hour access to advice. When they showed signs of contracting typhoid, or after 14 days, they received a course of antibiotics to cure them.

Oxford Vaccine Group is now analysing the data, with results to be announced during 2017 (Read More ....)

Similar stories

Oxford vaccine stimulates broad antibody and T cell functions

COVID-19 Publication Research

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.

SIMON Says…

Publication Research

Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.

Trial of Oxford COVID-19 vaccine in South Africa begins

COVID-19 Research

Participants in South Africa’s first clinical trial for a vaccine against COVID-19 are to be vaccinated this week.

Trial of Oxford COVID-19 vaccine starts in Brazil

COVID-19 Research

Volunteers have begun taking part in Latin America’s first clinical trial for a vaccine against COVID-19.

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit

COVID-19 Research

AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.